217 related articles for article (PubMed ID: 22198745)
1. Endostatin specifically targets both tumor blood vessels and lymphatic vessels.
Zhuo W; Chen Y; Song X; Luo Y
Front Med; 2011 Dec; 5(4):336-40. PubMed ID: 22198745
[TBL] [Abstract][Full Text] [Related]
2. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells.
Zhuo W; Luo C; Wang X; Song X; Fu Y; Luo Y
J Pathol; 2010 Nov; 222(3):249-60. PubMed ID: 20814900
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer.
Jia Y; Liu M; Huang W; Wang Z; He Y; Wu J; Ren S; Ju Y; Geng R; Li Z
Pathol Oncol Res; 2012 Apr; 18(2):315-23. PubMed ID: 21938482
[TBL] [Abstract][Full Text] [Related]
4. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice.
Brideau G; Mäkinen MJ; Elamaa H; Tu H; Nilsson G; Alitalo K; Pihlajaniemi T; Heljasvaara R
Cancer Res; 2007 Dec; 67(24):11528-35. PubMed ID: 18089781
[TBL] [Abstract][Full Text] [Related]
5. Identification of differentially expressed genes in a renal cell carcinoma tumor model after endostatin-treatment.
van Wijngaarden J; de Rooij K; van Beek E; Bernsen H; Que I; van Hinsbergh VW; Löwik C
Lab Invest; 2004 Nov; 84(11):1472-83. PubMed ID: 15273700
[TBL] [Abstract][Full Text] [Related]
6. Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies.
Tee D; DiStefano J
J Cancer Res Clin Oncol; 2004 Jan; 130(1):15-24. PubMed ID: 14586644
[TBL] [Abstract][Full Text] [Related]
7. Endostar, a recombined humanized endostatin, inhibits lymphangiogenesis and lymphatic metastasis of Lewis lung carcinoma xenograft in mice.
Dong X; Zhao X; Xiao T; Tian H; Yun C
Thorac Cardiovasc Surg; 2011 Apr; 59(3):133-6. PubMed ID: 21480131
[TBL] [Abstract][Full Text] [Related]
8. Endostatin suppresses colorectal tumor-induced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin α9.
Ou J; Li J; Pan F; Xie G; Zhou Q; Huang H; Liang H
J Cell Biochem; 2011 Aug; 112(8):2106-14. PubMed ID: 21465533
[TBL] [Abstract][Full Text] [Related]
9. Effect of human recombinant Endostatin protein on human angiogenesis.
Jung SP; Siegrist B; Hornick CA; Wang YZ; Wade MR; Anthony CT; Woltering EA
Angiogenesis; 2002; 5(1-2):111-8. PubMed ID: 12549868
[TBL] [Abstract][Full Text] [Related]
10. Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin.
Tan H; Yang S; Liu C; Cao J; Mu G; Wang F
Biomed Pharmacother; 2012 Dec; 66(8):648-54. PubMed ID: 23122594
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.
Anakha J; Dobariya P; Sharma SS; Pande AH
Med Oncol; 2023 Dec; 41(1):24. PubMed ID: 38123873
[TBL] [Abstract][Full Text] [Related]
12. [Endostar reduces the growth and metastasis by inhibiting angiogenesis and lymphangiogenesis in nude mouse models of human cervical cancer].
Jia YT; Li ZX; Liu M; Chen SA; Zhang L; Wang YD
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):254-7. PubMed ID: 19615276
[TBL] [Abstract][Full Text] [Related]
13. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model.
Tanabe K; Maeshima Y; Ichinose K; Kitayama H; Takazawa Y; Hirokoshi K; Kinomura M; Sugiyama H; Makino H
Kidney Int; 2007 Feb; 71(3):227-38. PubMed ID: 17191085
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
Folkman J
Exp Cell Res; 2006 Mar; 312(5):594-607. PubMed ID: 16376330
[TBL] [Abstract][Full Text] [Related]
15. A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway.
Choi JU; Chung SW; Al-Hilal TA; Alam F; Park J; Mahmud F; Jeong JH; Kim SY; Byun Y
Biomaterials; 2017 Sep; 139():56-66. PubMed ID: 28586719
[TBL] [Abstract][Full Text] [Related]
16. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor growth in mice by endostatin derived from abdominal transplanted encapsulated cells.
Teng H; Zhang Y; Wang W; Ma X; Fei J
Acta Biochim Biophys Sin (Shanghai); 2007 Apr; 39(4):278-84. PubMed ID: 17417683
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.
Dass CR; Tran TM; Choong PF
J Dent Res; 2007 Oct; 86(10):927-36. PubMed ID: 17890668
[TBL] [Abstract][Full Text] [Related]
20. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
